| Assessment Status | Rapid Review Complete |
| HTA ID | 22008 |
| Drug | Tafasitamab |
| Brand | Minjuvi® |
| Indication | In combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem-cell transplant (ASCT). |
| Assessment Process | |
| Rapid review commissioned | 14/02/2022 |
| Rapid review completed | 15/02/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tafasitamab in combination with lenalidomide compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
